A carregar...
Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models
Effective treatments for patients with mCRPC following disease progression on enzalutamide is currently an unmet clinical need. Simultaneous inhibition of the HIF-1α and AR pathways has been shown to overcome enzalutamide resistance in vitro. Combination treatment with NLG207, a nanoparticle-drug co...
Na minha lista:
| Publicado no: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8102325/ https://ncbi.nlm.nih.gov/pubmed/33632874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0228 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|